Ameriprise
SCLN

Ameriprise’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Ameriprise’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-307,087
Closed -$3.44M – 3818
2017
Q3 		$3.44M Buy
307,087
+24,685
+9% +$272K ﹤0.01% 2336
2017
Q2 		$3.11M Sell
282,402
-7,215
-2% -$72.2K ﹤0.01% 2383
2017
Q1 		$2.84M Buy
289,617
+13,470
+5% +$135K ﹤0.01% 2416
2016
Q4 		$2.98M Buy
276,147
+29,262
+12% +$293K ﹤0.01% 2421
2016
Q3 		$2.53M Buy
246,885
+7,250
+3% +$79K ﹤0.01% 2439
2016
Q2 		$3.13M Buy
+239,635
New +$3.14M ﹤0.01% 2274
2014
Q4 		– Sell
-888
Closed -$7K – 4877
2014
Q3 		$7K Buy
888
+148
+20% +$887 ﹤0.01% 5019
2014
Q2 		$4K Sell
740
-16,060
-96% -$78.1K ﹤0.01% 5035
2014
Q1 		$77K Sell
16,800
-35,840
-68% -$173K ﹤0.01% 3617
2013
Q4 		$265K Sell
52,640
-28,661
-35% -$138K ﹤0.01% 3046
2013
Q3 		$412K Buy
81,301
+230
+0.3% +$1.28K ﹤0.01% 2943
2013
Q2 		$402K Buy
+81,071
New +$386K ﹤0.01% 2880

Ameriprise's SCLN Position: Q4 2017 in Review

Ameriprise sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2017, closing a stake of 307,087 shares — an estimated $3.44M sold.

Ameriprise first reported a position in SCLN in Q2 2013 and held it in 12 quarters. The position peaked at $3.44M in Q3 2017. 0 funds tracked by Wall St. Rank hold SCLN as of Q4 2017.

  • Ameriprise reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
  • Ameriprise sold 307,087 Sciclone Pharmaceuticals Inc shares in Q4 2017, an estimated $3.44M.
  • Ameriprise first reported a position in Sciclone Pharmaceuticals Inc in Q2 2013 and held it in 12 quarters.
  • Ameriprise's Sciclone Pharmaceuticals Inc position peaked at $3.44M in Q3 2017.
  • 0 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2017.

Based on Ameriprise's 13F filing for Q4 2017, filed 12 Feb 2018.